US Oncology, Inc. Provides Full Service Management of Clinical Trials

HOUSTON, April 2 /PRNewswire/ -- US Oncology, the nation’s foremost cancer treatment and research network, has established US Oncology Clinical Development (USOCD), a full service contract research organization (CRO).

USOCD formalizes many of the services that US Oncology Research has provided since its inception in 1999. For more than a decade US Oncology Research has offered pharmaceutical and biotechnology companies elements of the clinical trial management process. The formation of USOCD focuses the company’s extensive resources in order to provide full service CRO capabilities with expertise in the following areas:

USOCD understands the complexities of oncology clinical trials and assists pharmaceutical and biotechnology companies in navigating the trial process to better manage their portfolio of products and expedite marketing approval. USOCD can identify key government and industry dynamics to intelligently plan and manage the enrollment strategy for clients.

“We have built an experienced team that enhances our ability to serve our clients for all of their oncology clinical trial needs,” said Steve Smith, vice president and general manager of Research and Personalized Science. “We will leverage all of the strengths of the US Oncology network and its proven history of accrual performance and commitment to quality.”

About US Oncology Clinical Development

US Oncology Clinical Development is a full service CRO providing high quality, cost efficient, customized research management and analytics to clients across the industry. To learn more about USOCD services, please contact us at http://www.usoncology.com/OurServices/ClinicalDev.asp.

About US Oncology

US Oncology, headquartered in the Houston area, works closely with physicians, payers, biotechnology, pharmaceutical and medical equipment manufacturers, to identify and deliver innovative services that enhance patient access to advanced cancer care. US Oncology supports one of the nation’s foremost cancer treatment and research networks, accelerating the availability and use of evidence-based medicine and shared best practices.

US Oncology uses its expertise to support every aspect of the cancer care delivery system--from drug development to distribution and outcomes measurement--enabling the company to help increase the efficiency and safety of cancer care. According to the company’s last quarterly earnings report, US Oncology is affiliated with 1,211 physicians operating in 456 locations, including 94 radiation oncology facilities in 39 states. For more information, visit the company’s Web site, www.usoncology.com.

CONTACT: Jennifer Horspool of US Oncology, Inc., +1-281-863-6739,
Jennifer.Horspool@usoncology.com

Web site: http://www.usoncology.com/

MORE ON THIS TOPIC